Discovery Labs to Report 2014 First Quarter Financial Results and Hold Conference Call on Thursday, May 8, 2014

May 06, 2014, 07:30 ET from Discovery Laboratories, Inc.

WARRINGTON, Pa., May 6, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report first quarter 2014 financial results on May 8, 2014 before the open of the U.S. financial markets. 

The Company will host a live teleconference and webcast at 9:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will discuss the 2014 first quarter financial results along with other business updates. 

The press release and the live webcast of the conference call will be available via Discovery Labs' corporate website at  The webcast will be made available on the events page.  An audio archive will be available after the call at the same address until Friday, June 6, 2014

To participate in the live conference call, please dial (877) 870-4263 (domestic) and (412) 317-0790 (international).  After placing the call, please use 10045704 as the passcode.  The conference call replay number is (877) 344-7529 (domestic) or (412) 317-0088 (international) using the same conference call password listed above.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care.  Discovery Labs' technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

For more information, please visit the Company's website at

SOURCE Discovery Laboratories, Inc.